Floatz logo

Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes

Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

Atara BiotherapeuticsCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Jennifer Amengual
Phase 2BBB
Cyclophosphamide
Washington University School of Medicine
Phase 2BBB
cc-5013
Northwestern University
Phase 2BB
Fludarabine
City of Hope Medical Center
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 49 →

Same molecule, other indications

Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:

Epstein-Barr virus-related tumorDormant
CCC
Indicative ·
52 / 100
View asset →
EBV-associated MalignanciesDormant
CCC
Indicative ·
52 / 100
View asset →
Epstein-Barr Virus-Related Hodgkin LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →